CCL21 is associated with fatal outcomes in chronic heart failure: data from CORONA and GISSI‐HF trials

Chronic heart failure (HF) is in part characterized by immune activation and inflammation, and factors that regulate lymphocyte trafficking and inflammation may contribute to the progression of this disorder. The homeostatic chemokine CCL21 is a potent regulator of T‐cell migration into non‐lymphoid tissue and may exert inflammatory properties and influence tissue remodelling. We therefore investigated CCL21 levels and association with fatal outcomes in patients with chronic HF.

[1]  K. Alitalo,et al.  Targeting Lymphatic Vessel Activation and CCL21 Production by Vascular Endothelial Growth Factor Receptor-3 Inhibition Has Novel Immunomodulatory and Antiarteriosclerotic Effects in Cardiac Allografts , 2010, Circulation.

[2]  F. Martinez,et al.  Idiopathic pulmonary fibrosis fibroblasts migrate and proliferate to CC chemokine ligand 21 , 2007, European Respiratory Journal.

[3]  G. Lip,et al.  The role of monocytes and inflammation in the pathophysiology of heart failure , 2011, European journal of heart failure.

[4]  John G F Cleland,et al.  Predictors of fatal and non‐fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A‐1, high‐sensitivity C‐reactive peptide and N‐terminal pro B‐type natriuretic peptide , 2009, European journal of heart failure.

[5]  J. McMurray,et al.  A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): Study design and baseline characteristics , 2005, European journal of heart failure.

[6]  H. Fillit,et al.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.

[7]  A. Rot,et al.  CCR7 is required for the in vivo function of CD4+ CD25+ regulatory T cells , 2007, The Journal of experimental medicine.

[8]  L. Tavazzi,et al.  Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. , 2008, Lancet.

[9]  T. Ueland,et al.  Role of inflammation in the progression of heart failure , 2007, Current cardiology reports.

[10]  Antal Rot,et al.  CCR7 and its ligands: balancing immunity and tolerance , 2008, Nature Reviews Immunology.

[11]  Gissi-Hf Investigators.  Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[12]  J. McMurray,et al.  Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). , 2009, Journal of the American College of Cardiology.

[13]  L. Tavazzi,et al.  Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n‐3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure , 2004, European journal of heart failure.

[14]  T. Ueland,et al.  Chemokines and Cardiovascular Risk , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[15]  B. Bozkurt,et al.  Biomarkers of inflammation in heart failure , 2010, Heart Failure Reviews.

[16]  L. Tavazzi,et al.  The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI‐heart failure (GISSI‐HF) trial , 2010, European journal of heart failure.

[17]  P. Hohensinner,et al.  Macrophage-modulating cytokines predict adverse outcome in heart failure , 2010, Thrombosis and Haemostasis.

[18]  Ewout W Steyerberg,et al.  Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers , 2011, Statistics in medicine.

[19]  K. Dickstein,et al.  The Homeostatic Chemokine CCL21 Predicts Mortality and May Play a Pathogenic Role in Heart Failure , 2012, PloS one.

[20]  D. Bates,et al.  Chemotrap-1: an engineered soluble receptor that blocks chemokine-induced migration of metastatic cancer cells in vivo. , 2010, Cancer research.

[21]  U. Höpken,et al.  Distinctive role of CCR7 in migration and functional activity of naive‐ and effector/memory‐like Treg subsets , 2007, European journal of immunology.

[22]  B. Fevang,et al.  Enhanced Expression of the Homeostatic Chemokines CCL19 and CCL21 in Clinical and Experimental Atherosclerosis: Possible Pathogenic Role in Plaque Destabilization , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[23]  L. Tavazzi,et al.  Pentraxin‐3 in chronic heart failure: the CORONA and GISSI‐HF trials , 2012, European journal of heart failure.

[24]  M. Clearfield.  Rosuvastatin in older patients with systolic heart failure. , 2009, Current atherosclerosis reports.